Novartis’s Sandoz spin-off and Sanofi’s portfolio slim-down reflect pharma push toward specialization

[Gorodenkoff/Adobe Stock]

Modern pharma: Evolving through specialized strategies

The pharmaceutical trend toward increasing concentration appears to be gaining momentum. On September 15, Novartis shareholders approved the company’s proposed spinoff of Sandoz, the generics and biosimilars unit. The company anticipates the deal to close in early October. Similarly, Sanofi is also taking a scalpel to its operations, offloading a selection of its central nervous system medications to Pharmanovia.

Sanofi, similar to several other of its pharma peers, is aiming to realign its portfolio, emphasizing areas where it can drive innovation and deliver robust growth.

Last week, Johnson & Johnson, for instance, announced a rebrand that traded its historic ‘Janssen’ pharma moniker for ‘Johnson & Johnson Innovative Medicine.’ The move is part of a broader initiative to priorit…

Read more
  • 0

Aphena reveals plans for third-party logistics division

Aphena Pharma Solutions has announced the launch of a Third-Party Logistics (3PL) Division at its campus in Cookeville, Tenn. The pharmaceutical packaging and manufacturing company plans to complete the new division by the end of the year and serve new clients in early 2022. The 3PL unit will cater to the prescription pharmaceutical market, focusing on generics, OTC drugs, and nutraceutical/homeopathic medicines.

In addition to distribution services, the 3PL division will offer accounting services, cold chain services, controlled room temperature storage, and DEA schedule II (vault) and DEA schedule III-V storage. Additionally, the company is pursuing NABP’s Drug Distributor Accreditation.

Last week, the company announced that it had named Troy Blodgett the vice president and general manager of its 3PL division.

At the start of the year, the company announced that it was nearly finished with a $21 million, 500,000 ft2 expansion.


Read more
  • 0